(AOF) – Predilife, a specialist in innovative pathology risk prediction solutions for personalized medicine, announces the success of its public offering of bonds convertible or exchangeable for new or existing shares (the “OCEANEs”), maturing in 2028 , opened on June 1, 2023. The offer, open to the public for an amount of 1.995 million euros, was subscribed for an amount of 1.865 million euros, i.e. 93%.
The proceeds of the offer will be mainly allocated to the financing of marketing and commercial investments, thus making it possible to intensify the deployment of prevention assessments among companies of all sizes and in all sectors.
The net proceeds of the issue, equal to approximately 1.6 million euros (after deduction of the costs inherent in the offer), are intended to finance the company’s activities at least until January 2025.
The registration of the OCEANEs will take place on July 28, 2023.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.